Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

10105	Companies
207050	Keywords
137195	Articles
109737	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 02/17/2025 at 08:05, 1 year 1 month ago

EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III trial for FYB206 after FDA feedback, anticipates valuation adjustments for FYB202 & FYB201 due to price discounts

FDA Feedback Valuation Adjustments Formycon FYB206 Price Discounts
BRIEF

published on 02/05/2025 at 06:35, 1 year 1 month ago

Lotus Pharmaceutical Partners with Formycon to Commercialize Eylea® Biosimilar in Asia-Pacific

Lotus Pharmaceutical Eylea® Biosimilar Asia-Pacific Commercialization FDA And EU Approval Retinal Disease Treatment
BRIEF

published on 02/05/2025 at 06:35, 1 year 1 month ago

Lotus Pharmaceutical s'associe à Formycon pour commercialiser le biosimilaire Eylea® en Asie-Pacifique

Lotus Pharmaceutique Biosimilaire Eylea® Commercialisation En Asie-Pacifique Approbation De La FDA Et De L'UE Traitement Des Maladies De La Rétine
PRESS RELEASE

published on 02/05/2025 at 06:30, 1 year 1 month ago

Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
Formycon AG announces strategic partnership with Lotus Pharmaceutical for commercialization of Eylea biosimilar FYB203/AHZANTIVE in Asia-Pacific region

Formycon AG Asia-Pacific Eylea Biosimilar FYB203/AHZANTIVE Lotus Pharmaceutical
BRIEF

published on 01/20/2025 at 06:35, 1 year 2 months ago

Formycon Secures EU Approval for Biosimilar FYB203

Formycon AG EU Approval Teva Pharmaceuticals Aflibercept Biosimilar FYB203
BRIEF

published on 01/20/2025 at 06:35, 1 year 2 months ago

Formycon obtient l'approbation de l'UE pour le biosimilaire FYB203

Formycon AG Teva Pharmaceuticals Aflibercept Homologation UE Biosimilaire FYB203
PRESS RELEASE

published on 01/20/2025 at 06:30, 1 year 2 months ago

Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Formycon receives EU approval for biosimilar FYB203 (aflibercept) to Eylea®, brands AHZANTIVE® and Baiama® for nAMD and retinal diseases. Teva to market AHZANTIVE® in Europe

Biosimilar Formycon EU Approval AHZANTIVE Baiama
BRIEF

published on 01/15/2025 at 06:35, 1 year 2 months ago

MHRA Grants Approval for Formycon and Fresenius Kabi's Otulfi®

Formycon Fresenius Kabi Ustekinumab Biosimilar Approval Otulfi® Launch
BRIEF

published on 01/15/2025 at 06:35, 1 year 2 months ago

La MHRA accorde son approbation à Formycon et à Otulfi® de Fresenius Kabi

Formycon Fresenius Kabi Ustekinumab Approbation Des Biosimilaires Lancement D'Otulfi®
PRESS RELEASE

published on 01/15/2025 at 06:30, 1 year 2 months ago

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi®, a biosimilar to Stelara®, for various inflammatory diseases. Global biosimilar approval news

Biosimilar Formycon Fresenius Kabi FYB202 MHRA Approval

Accesswire

Published on 03/27/2026 at 15:35, 2 hours 8 minutes ago

SouthGobi Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Published on 03/27/2026 at 12:30, 5 hours 13 minutes ago

Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 5 hours 43 minutes ago

Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 12:00, 5 hours 43 minutes ago

Athena Gold Announces Share Consolidation
Published on 03/27/2026 at 11:00, 6 hours 43 minutes ago

RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation

View all ACCESSWIRE

EQS Group

Published on 03/27/2026 at 17:30, 12 minutes ago

Holding(s) in Company
Published on 03/27/2026 at 15:58, 1 hour 44 minutes ago

coinIX remains resilient in volatile market environment with balanced annual result | CEO Moritz Schildt sees entry-level prices in the crypto market
Published on 03/27/2026 at 15:50, 1 hour 52 minutes ago

EQS-Adhoc: Klöckner & Co SE: Worthington Steel announces intention to enter into a domination and profit and loss transfer agreement with Klöckner & Co SE
Published on 03/27/2026 at 15:05, 2 hours 37 minutes ago

Huawei's 6th Global Installer Summit: Gathering the Best Installers to Embrace Renewable Energy Opportunities in the AI Era
Published on 03/27/2026 at 14:31, 3 hours 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc

Les Echos

Published on 03/27/2026 at 17:40, 3 minutes ago

Creation of a General Operations Department
Published on 03/27/2026 at 17:40, 3 minutes ago

Assemblée générale mixte du 22 avril 2026 Modalités de mise à disposition des documents préparatoires
Published on 03/27/2026 at 17:40, 3 minutes ago

Création d’une Direction générale des opérations
Published on 03/27/2026 at 07:00, 10 hours 43 minutes ago

WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 23 hours 26 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital

View all LES ECHOS COMFI WIRE